Electra Therapeutics closed a $183 million Series C to fund a pivotal trial of ELA026, its monoclonal antibody for secondary hemophagocytic lymphohistiocytosis (HLH), and to advance a second preclinical program toward the clinic. The round was co-led by Nextech and EQT Life Sciences and drew strategic investors including Sanofi. Electra said the financing will support the ongoing Phase 2/3 study and expand work in blood cancers where the SIRP-targeting approach may be relevant. CEO Kathy Dong emphasized the scientific rationale for targeting SIRP-expressing myeloid and T cells; investors and partners will watch clinical enrollment, safety, and efficacy readouts as the company executes its pivotal plan.